Please login to the form below

Not currently logged in
Email:
Password:

RRMS

This page shows the latest RRMS news and features for those working in and with pharma, biotech and healthcare.

Roche’s Ocrevus boasts positive long-term data in MS

Roche’s Ocrevus boasts positive long-term data in MS

Swiss pharma company Roche has released new long-term data that shows 75% of relapsing-remitting multiple sclerosis (RRMS) patients treated with Ocrevus (ocrelizumab) had no evidence of disease activity after ... Following two years of using Ocrevus twice

Latest news

More from news
Approximately 8 fully matching, plus 31 partially matching documents found.

Latest from PMHub

  • Innovative approaches in the treatment of multiple sclerosis

    THE TWO TYPES OF MS. There are two main clinical presentations of MS – Relapsing Refractory MS (RRMS) and Progressive MS (PMS). ... In RRMS symptoms are intermittent but relapses gradually become more frequent, severe and longer-lasting as the disease

  • Innovative approaches in the treatment of multiple sclerosis

    THE TWO TYPES OF MS. There are two main clinical presentations of MS – Relapsing Refractory MS (RRMS) and Progressive MS (PMS). ... In RRMS symptoms are intermittent but relapses gradually become more frequent, severe and longer-lasting as the disease

  • It's time to change the conversation

    Take Multiple Sclerosis (MS) for example. MS has four different disease manifestations: Relapsing Remitting (RRMS), Secondary Progressive (SPMS), Primary Progressive (PPMS) and Progressive Relapsing (PRMS). ... Today however, given the research and the

More from PMHub
Approximately 0 fully matching, plus 3 partially matching documents found.

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Research Partnership

We are the largest independent healthcare market research and consulting agencies in the world. Trusted partner to the global pharmaceutical...

Latest intelligence

What’s in it for me? How to engage, motivate and support staff with internal training at OPEN Health
...
Environmental impact of in-person vs. virtual meetings
Although it will be tempting to resume in-person activities in the same capacity as before, we need to weigh the pros and cons of virtual vs. in-person vs. hybrid events...
US biosimilars
The US celebrates five years of biosimilars on the market – a look to the past, present and future
Why the success of biosimilars in the US has been mixed...

Infographics